NCT00995605终止1 期
AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- AnaMar AB
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Safety and tolerability determined by adverse events, vital signs, ECG and clinical laboratory evaluations
研究概览
简要总结
The purpose of this study is to determine whether AMAP102 is safe and well tolerated by humans.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In Groups A, B, D, E and F, subjects will be males of any ethnic origin between 18 and 65 years of with a BMI between 20.0 and 30.0 kg/m2
- •In Group C, subjects will be females (of non-childbearing potential) of any ethnic origin between 18 and 65 years with a BMI between 20.0 and 28.0 kg/m2
- •For Group C, women will be of non-childbearing potential, defined as surgically sterile or post-menopausal, non-lactating and having a negative serum pregnancy test
- •Subjects must be in good health, as determined by a medical history, physical examination, 12-lead ECG and clinical laboratory evaluations
- •Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions
排除标准
- •Male subjects who are not willing to use appropriate contraception from the time of the first dose until 3 months after the final dosing occasion
- •Subjects who have received any prescribed systemic or topical medication within 14 days of the first dose administration
- •Subjects who have used any non-prescribed systemic or topical medication within 7 days of the first dose administration
- •Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration
- •Subjects who are still participating in a clinical study or who have participated in a clinical study involving administration of an investigational drug in the past 3 months
- •Subjects who have donated any blood, plasma or platelets in the month prior to screening or who have made donations on more than two occasions within the 12 months preceding the first dose administration
- •Subjects with a significant history of drug allergy as determined by the Investigator
- •Subjects who have any clinically significant allergic disease as determined by the Investigator
- •Subjects who have a supine blood pressure and supine pulse rate higher than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50 mmHg and 40 bpm, respectively
- •Subjects who consume more than 28 units (males) or more than 21 units (females) of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse as determined by the Investigator (one unit of alcohol equals ½ pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits)
- •Subjects who smoke more than 10 cigarettes or the equivalent in tobacco per day
- •Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorders as determined by the Investigator
- •Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator
- •Subjects who are known to have serum hepatitis, or who are carriers of the HBsAg or hepatitis C antibody, or who have a positive result to the test for HIV antibodies
- •Subjects who have an abnormality in the 12-lead ECG such that, in the opinion of the investigator, increases the risk of participating in the study, such as QTc(b) interval greater than 430 msec (male) or greater than 450 msec (female), 2nd or 3rd degree Atrioventricular block, complete left bundle branch block, complete right bundle branch block or Wolff-Parkinson-White Syndrome, defined as PR shorter than 110 msec, confirmed by a repeat ECG
- •Subjects with a significant cardiac history (e.g. heart failure, hypokalemia, long QT syndrome), significant history of fainting, syncope or family history of sudden cardiac death
- •Subjects who, in the opinion of the Investigator, should not participate in the study
研究组 & 干预措施
Groups SAD
Experimental
AMAP102 or Placebo as single ascending doses in five groups
干预措施: AMAP102 (Drug)
Groups MAD
Experimental
AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
干预措施: AMAP102 (Drug)
结局指标
主要结局
Safety and tolerability determined by adverse events, vital signs, ECG and clinical laboratory evaluations
时间窗: During residential period and at follow up visit
次要结局
- Investigate the pharmacokinetic profile of AMAP102 after one oral dose and after multiple oral doses during twice daily dosing for seven days, and compare the pharmacokinetic profile for men and women(PK sampling at defined timepoints during residential period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic UlcersIschemiaUlcersArterial Occlusive DiseasePeripheral Vascular DiseaseNCT00189540AnGes USA, Inc.27
已完成
2 期
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisALSNCT05163886OrphAI Therapeutics14
已完成
1 期
Single Ascending Dose Study of NH102 in Healthy SubjectsDepressionNCT05015192Jiangsu Nhwa Pharmaceutical Co., Ltd.55
已完成
2 期
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)Autism Spectrum Disorder (ASD)NCT04895215Vertero Therapeutics156
已完成
2 期
Arbaclofen in Children and Adolescents With ASDAutism Spectrum DisorderNCT03682978Celso Arango, MD, PhD124